WO2004052305A3 - Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease - Google Patents

Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease Download PDF

Info

Publication number
WO2004052305A3
WO2004052305A3 PCT/US2003/039265 US0339265W WO2004052305A3 WO 2004052305 A3 WO2004052305 A3 WO 2004052305A3 US 0339265 W US0339265 W US 0339265W WO 2004052305 A3 WO2004052305 A3 WO 2004052305A3
Authority
WO
WIPO (PCT)
Prior art keywords
lactoferrin
graft
versus
host
disease
Prior art date
Application number
PCT/US2003/039265
Other languages
French (fr)
Other versions
WO2004052305A2 (en
Inventor
Atul Varadhachary
Federica Pericle
Original Assignee
Agennix Inc
Atul Varadhachary
Federica Pericle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agennix Inc, Atul Varadhachary, Federica Pericle filed Critical Agennix Inc
Priority to AU2003296447A priority Critical patent/AU2003296447A1/en
Publication of WO2004052305A2 publication Critical patent/WO2004052305A2/en
Publication of WO2004052305A3 publication Critical patent/WO2004052305A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to methods of using lactoferrin (LF) to treat, prevent or reduce the incidence of organ transplant rejection and graft-versus-host-disease. More particularly, the present invention relates to methods of reducing an immune response against miss-matched transplanted organs such as kidney, heart, lung, liver, pancreas and stem cells by administering a composition of lactoferrin to the recipient patients. In addition, this invention relates to the treatment of bone marrow transplant (BMT) donors with lactoferrin to attenuate the development of graft-versus-host-disease in the recipients. Moreover, this invention relates to the treatment of xenograft organ donors with lactoferrin to attenuate the development of graft rejection in the recipients.
PCT/US2003/039265 2002-12-10 2003-12-10 Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease WO2004052305A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003296447A AU2003296447A1 (en) 2002-12-10 2003-12-10 Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43211302P 2002-12-10 2002-12-10
US60/432,113 2002-12-10
US49833803P 2003-08-27 2003-08-27
US60/498,338 2003-08-27

Publications (2)

Publication Number Publication Date
WO2004052305A2 WO2004052305A2 (en) 2004-06-24
WO2004052305A3 true WO2004052305A3 (en) 2005-06-16

Family

ID=32511629

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/039265 WO2004052305A2 (en) 2002-12-10 2003-12-10 Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease

Country Status (3)

Country Link
US (2) US7592306B2 (en)
AU (1) AU2003296447A1 (en)
WO (1) WO2004052305A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1545587T3 (en) 2002-09-16 2011-05-09 Agennix Inc Lactoferrin compositions and methods for the treatment of diabetic wounds
CA2508912A1 (en) * 2002-12-06 2004-06-24 Agennix Incorporated Oral lactoferrin in the treatment of sepsis
AU2003296447A1 (en) 2002-12-10 2004-06-30 Agennix Incorporated Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
US8105615B2 (en) * 2003-06-06 2012-01-31 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
WO2006047744A2 (en) * 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
WO2008113134A1 (en) * 2007-03-20 2008-09-25 Garvan Institute Of Medical Research Method of transplantation of a kidney
MX348337B (en) 2010-11-26 2017-06-07 Evonik Roehm Gmbh Human lactoferrin derived peptide for use as an antigen masking agent.
WO2017189480A1 (en) * 2016-04-27 2017-11-02 Yale University Compositions and methods for grafts modified with a non-thrombogenic and pro-migratory cell-derived extracellular matrix

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6333311B1 (en) * 1997-02-03 2001-12-25 Pharming Useful properties of human lactoferrin and variants thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977137B1 (en) * 1987-06-03 1994-06-28 Baylor College Medicine Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract
US5006333A (en) * 1987-08-03 1991-04-09 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5766939A (en) * 1989-05-05 1998-06-16 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5571697A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Texas Medical Center Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
US5849881A (en) * 1989-05-05 1998-12-15 Baylor College Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms
US5571691A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
IL94183A (en) * 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
US6100054A (en) * 1989-05-05 2000-08-08 Baylor College Of Medicine Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms
EP0426924A1 (en) 1989-11-09 1991-05-15 Cellena (Cell Engineering) A.G. Production of metal transporter compositions for facilitating the engraftment of histo-incompatible bone marrow and controlling the immune reactions in the recipient host
US5198419A (en) * 1989-12-08 1993-03-30 Immuno Japan Inc. Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria
US6066469A (en) * 1990-03-08 2000-05-23 Ferro Dynamics, Inc. Cloning, expression, and uses of human lactoferrin
ZA932568B (en) * 1992-04-24 1993-11-12 Baylor College Midecine A Non Production of recombinant human lactoferrin
US5861491A (en) * 1994-02-16 1999-01-19 Pharming B.V. Isolation of lactoferrin from milk
JPH07316069A (en) 1994-05-24 1995-12-05 Tokushu Meneki Kenkyusho:Kk Composition for preventing and treating opportunistic infection
US5712247A (en) * 1995-02-21 1998-01-27 University Of North Carolina Use of lactoferrin to modulate and/or neutralize heparin activity
US5674495A (en) * 1995-02-27 1997-10-07 Purdue Research Foundation Alginate-based vaccine compositions
US6111081A (en) * 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof
CN1262625A (en) * 1997-04-10 2000-08-09 阿吉尼克斯股份有限公司 Use of lactoferin in treatment of allergen induced disorders
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
AU3075801A (en) * 1999-12-23 2001-07-03 Human Genome Sciences, Inc. Transferrin polynucleotides, polypeptides, and antibodies
WO2001072322A2 (en) 2000-03-27 2001-10-04 Pharming Intellectual Property B.V. High dosage parenteral administration of lactoferrin
RU2165769C1 (en) 2000-07-13 2001-04-27 Якубовская Раиса Ивановна Antibacterial, antioxidant, immunomodulating and anticancer preparation and method of its embodiment
WO2003020746A1 (en) * 2001-08-30 2003-03-13 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
CN100467059C (en) * 2002-05-10 2009-03-11 阿根尼克斯有限公司 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
AU2003233583A1 (en) * 2002-05-24 2003-12-12 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
DK1545587T3 (en) * 2002-09-16 2011-05-09 Agennix Inc Lactoferrin compositions and methods for the treatment of diabetic wounds
AU2003291206A1 (en) * 2002-12-04 2004-06-23 Agennix Incorporated Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease
CA2508912A1 (en) * 2002-12-06 2004-06-24 Agennix Incorporated Oral lactoferrin in the treatment of sepsis
AU2003296447A1 (en) 2002-12-10 2004-06-30 Agennix Incorporated Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
AU2003293500A1 (en) * 2002-12-12 2004-07-09 Agennix Incorporated Lactoferrin in the reduction of pain
WO2004103285A2 (en) * 2003-05-14 2004-12-02 Agennix Incorporated Lactoferrin in the treatment of diabetes mellitus
US8105615B2 (en) * 2003-06-06 2012-01-31 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
WO2005018542A2 (en) * 2003-07-10 2005-03-03 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6333311B1 (en) * 1997-02-03 2001-12-25 Pharming Useful properties of human lactoferrin and variants thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KUNZENDORF U.: "The Th1-Th2 paradign in 1998: law of nature or rule with exception", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 13, 1998, pages 2445 - 2448, XP002986511 *
NIKOLIC B. ET AL.: "Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 15, no. 9, May 2000 (2000-05-01), pages 1289 - 1298, XP002986512 *

Also Published As

Publication number Publication date
US8058234B2 (en) 2011-11-15
US7592306B2 (en) 2009-09-22
AU2003296447A8 (en) 2004-06-30
US20090318334A1 (en) 2009-12-24
WO2004052305A2 (en) 2004-06-24
AU2003296447A1 (en) 2004-06-30
US20040176276A1 (en) 2004-09-09

Similar Documents

Publication Publication Date Title
DE60235928D1 (en) Agent for suppression of transplant rejection
JP2003277293A5 (en)
WO2007035843A3 (en) Methods and compositions for organ and tissue functionality
HUP0303930A2 (en) Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
WO2003000114A3 (en) Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
WO2009045360A3 (en) Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
WO2004101758A3 (en) Composition for maintaining organ and cell viability
TW200602078A (en) Uses of anti-CTLA-4 antibodies
MXPA02007137A (en) Liver tissue source.
WO2003012060A3 (en) Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd
WO2006060309A3 (en) Compositions and methods for ex vivo preservations of organs
WO2004052305A3 (en) Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
DE602004018547D1 (en) PREPARATION OF TACROLIMUS (FK-506) USING NEW STREPTOMYCES SPECIES
WO2002024244A3 (en) Method of preparing and processing transplant tissue
BR9612821A (en) Methods for preventing graft rejection in transplantation and for producing a host cell for universal gene therapy
WO2003102162A3 (en) Novel tolerogenic dendritic cells and therapeutic uses therefor
WO2002017935A3 (en) A method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease
DE60329226D1 (en) METHOD FOR SUPPRESSING AN IMMUNE SYSTEM REACTION AGAINST TISSUE OR CELL TRANSPLANTS
HK1060855A1 (en) Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment ofdelayed graft function
GB9928136D0 (en) Organ rejection and associated conditions
WO2005041877A3 (en) Method of inhibiting rejection following organ transplantation
WO2009107088A3 (en) Method for producing an implantable bone composition
WO2006031539A3 (en) Liver stromal cells for prevention and treatment of immune responses in transplantation
WO2007134908A3 (en) Use of thymosin alpha 1 for the treatment of immunological diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP